This article was originally published in Start Up
Sistemic Ltd. provides drug discovery and repositioning services using its microRNA compound-centric technology. The idea behind the SistemRNA platform is that microRNA is a high-level regulator in the cell, affecting critical pathways. As there are only around 1,000 mammalian microRNAs, it is feasible to monitor the levels of these in health and disease, and in response to drugs, creating microRNA profi les that reflect the biological response of the cell to Sistemic’s partners’ candidates.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Despite Challenges, Congestive Heart Failure Draws A Crowd," features profiles of miRagen, NellOne Therapeutics, Phrixus Pharmaceuticals and Sorbent Therapeutics. Plus these Start-Ups Across Health Care: Ambicare, Anulex Technologies, NeoTract and Sistemic.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.